SCHEMBL4885955

SCHEMBL4885955

COC(=O)C(C(N)=O)c1ccccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MEN1 O00255 1/20 0.49
GAA P10253 1/20 0.49
ALDH1A1 P00352 5/20 0.46
KDM4E B2RXH2 3/20 0.43
CYP3A4 P08684 2/20 0.43
TSHR P16473 2/20 0.43
ABCB11 O95342 1/20 0.43
LMNA P02545 1/20 0.43
ESR1 P03372 1/20 0.43
ADRA2A P08913 1/20 0.43
CYP2C9 P11712 1/20 0.43
PDE4A P27815 1/20 0.43
ADRA1A P35348 1/20 0.43
OPRK1 P41145 1/20 0.43
STAT6 P42226 1/20 0.43
SLC6A3 Q01959 1/20 0.43
HIF1A Q16665 1/20 0.43
GPR55 Q9Y2T6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16166404 0.87 SMN1; SMN2 (0.61) KMT2ASMN1; SMN2MEN1GAAALDH1A1
SCHEMBL27389459 0.87 KMT2A (0.49) KMT2ASMN1; SMN2MEN1GAAALDH1A1
SCHEMBL438354 0.84 CYP1A2 (0.47) KMT2ASMN1; SMN2MEN1GAAALDH1A1
SCHEMBL2390792 0.81 KMT2A (0.47) KMT2ASMN1; SMN2MEN1GAAALDH1A1
SCHEMBL20993618 0.81 KMT2A (0.47) KMT2ASMN1; SMN2MEN1GAAALDH1A1
SCHEMBL12259663 0.81 KMT2A (0.47) KMT2ASMN1; SMN2MEN1GAAALDH1A1
SCHEMBL20993624 0.81 KMT2A (0.47) KMT2ASMN1; SMN2MEN1GAAALDH1A1
SCHEMBL11036187 0.81 CYP3A4 (0.46) KMT2ASMN1; SMN2MEN1GAAALDH1A1
SCHEMBL6641796 0.79 KMT2A (0.48) KMT2ASMN1; SMN2MEN1GAAALDH1A1
SCHEMBL1028262 0.79 CYP1A2 (0.57) KMT2ASMN1; SMN2MEN1GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 US disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES SCN3A, TRPV3, HCN3 KMT2A 2659/4885SMN1; SMN2 599/4885MEN1 4543/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 KMT2A 2659/4885SMN1; SMN2 599/4885MEN1 4543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.